Document Detail


"Long term evaluation of combined treatment of Parkinson disease with L-dopa, peripheral decarboxylase inhibitors and bromocreptine".
MedLine Citation:
PMID:  7333824     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In this study the author's experience of Parkinson Disease treatment with long-term Bromocriptine (Br) administration, is summarized. Br, which acts directly on dopaminergic receptors, was introduced in combination with L-Dopa and peripheral decarboxylase inhibitors (PDI). The reasons for this association were: 1) the reduced effectiveness of the current treatment (L-Dopa + PDI) 2) onset of AIM (abnormal involuntary movements). 3) patient's desire to try new drugs. Only the patients who had been on the triple association for at least a year, were considered. Therefore of 50 patients originally considered only 19 were included in this study. The addition of Br allowed a reduction of the mean daily dose of L-Dopa(30%) and the therapeutic efficacy of the drug remained unchanged even after more than 4 years treatment. The "on-off" effect and AIM, are reduced by Br especially in the first months of treatment. The triple association is regarded at present as the best treatment for Parkinson disease.
Authors:
T Caraceni; P Giovannini; F Girotti; E Parati; M Pederzoli; G Scigliano
Related Documents :
11455084 - Use of a novel contingency stimulator in unilateral spatial neglect.
21372564 - Evaluation of different perfusion durations in direct hemoperfusion with polymyxin b-im...
21343714 - How is electrocardiogram influenced by electroconvulsive therapy in males and females?
21540774 - 5-year follow-up evaluation of surgical treatment for cervical myelopathy caused by oss...
20648434 - Prognostic value of pleural effusion, ca-125 and nt-probnp in patients with acute decom...
173124 - Immune responses to treatment with natural and synthetic acth in bronchial asthma.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Italian journal of neurological sciences     Volume:  2     ISSN:  0392-0461     ISO Abbreviation:  Ital J Neurol Sci     Publication Date:  1981 Dec 
Date Detail:
Created Date:  1982-05-27     Completed Date:  1982-05-27     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8006502     Medline TA:  Ital J Neurol Sci     Country:  ITALY    
Other Details:
Languages:  eng     Pagination:  337-42     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Antiparkinson Agents / administration & dosage*,  adverse effects
Bromocriptine / administration & dosage*,  adverse effects
Carboxy-Lyases / antagonists & inhibitors*
Drug Therapy, Combination
Female
Humans
Levodopa / administration & dosage*,  adverse effects
Male
Middle Aged
Parkinson Disease / drug therapy*
Parkinson Disease, Postencephalitic / drug therapy
Chemical
Reg. No./Substance:
0/Antiparkinson Agents; 0/Levodopa; 25614-03-3/Bromocriptine; EC 4.1.1.-/Carboxy-Lyases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Plasmapheresis in the treatment of four cases of Guillain-Barré syndrome (acute form).
Next Document:  The problem of subclinical localised paroxysmal rhythmic discharges (psychomotor variant discharges)...